Avastin Approved for Late-Stage Cervical Cancer
More than 4,000 women projected to die this year from the disease
FRIDAY, Aug. 15, 2014 (HealthDay News) -- The anti-cancer drug Avastin (bevacizumab) has been newly approved to treat aggressive and late-stage cervical cancer, the U.S. Food and Drug Administration said in a news release.
Cervical cancer is most often caused by the sexually spread human papillomvirus (HPV). More than 12,000 women in the United States will be diagnosed with the disease this year and more than 4,000 women will die from the illness, according to U.S. National Cancer Institute statistics.
Avastin works by interfering with the development of blood vessels that fuel cancerous cell growth. The new approval is for use in combination with other anti-cancer drugs, including paclitaxel, cisplatin and topotecan, the FDA said.
Avastin's safety and effectiveness in treating cervical cancer were evaluated in clinical studies involving 452 people with persistent, recurring or late-stage disease, the agency said. Average survival among those who took Avastin and chemotherapy drugs was 16.8 months, compared to 12.9 months among those receiving chemotherapy alone.
The most common side effects of Avastin included fatigue, loss of appetite, high blood pressure, increased blood sugar, decreased blood magnesium, urinary tract infection, headache and weight loss. Some users also developed perforations or abnormal openings of the gastrointestinal tract and vagina, the FDA said.
Avastin is marketed by San Francisco-based Genentech, a member of the Roche Group.
Visit the FDA (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410121.htm ) to learn more.
Please note, not all procedures included in this resource library are available at Henry Ford Allegiance Health or performed by Henry Ford Allegiance Health physicians.
All EBSCO Publishing proprietary, consumer health and medical information found on this site is accredited by URAC. URAC's Health Web Site Accreditation Program requires compliance with 53 rigorous standards of quality and accountability, verified by independent audits. To send comments or feedback to our Editorial Team regarding the content please email us at HLEditorialTeam@ebscohost.com.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.